BOSTON, May 23, 2024 /PRNewswire/ -- Servier, a global leader in oncology focused on delivering meaningful therapeutic progress for the patients it serves, will showcase data from across its oncology portfolio at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31-June 4. New data including two abstracts highlight Servier's continued leadership in IDH-inhibition.
BOSTON, May 14, 2024 /PRNewswire/ -- Servier, a leader in oncology committed to delivering transformative therapies to patients, is No. 1 in six categories, among 37 companies featured in PatientView's 2023-2024 Corporate Reputation of Pharma survey. This annual survey includes feedback from more than 300 patient organizations on their perceptions, experiences and familiarity with pharmaceutical companies.
A French drugmaker has hopped across the pond and stolen the hearts of U.S. patient groups.
An Indian industrialist wants to buy Biogaran, the French number one in generics
InnONE presentation with Pascal Baraffe, General Manager in Arklow site
BOSTON, April 8, 2024 /PRNewswire/ -- Servier, a science driven company focused on developing transformative precision therapies for patients, is poised to unveil promising preliminary data at the American Association for Cancer Research (AACR) Annual Meeting 2024. These submissions also demonstrate Servier's commitment to its One Innovation Engine approach to scientific advancements.
BOSTON and SURESNES, France, Feb. 21, 2024 /PRNewswire/ -- Servier, a global leader in oncology focused on delivering meaningful therapeutic progress for the patients it serves, today announced the FDA filing acceptance and priority review for a New Drug Application (NDA) for vorasidenib, as well as the EMA granting accelerated assessment for the vorasidenib Marketing Authorization Application (MAA). This innovative targeted therapy is an oral, selective, highly brain-penetrant dual inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1/2) enzymes for the treatment of IDH-mutant diffuse glioma. If approved, vorasidenib would become a first-in-class targeted therapy for patients with IDH-mutant gliomas and would mark Servier's sixth approval across IDH-mutant cancers. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of August 20, 2024, while the European Commission approval is anticipated in the second half of 2024.
FDA and EMA Accept Vorasidenib Regulatory Submissions for diffuse glioma
DURHAM, N.C., Jan. 5, 2024 /PRNewswire/ -- Base4 Biotechnology (formerly known as Nymirum) today announced that it has expanded its license agreement with Servier to strengthen the companies' strategic collaboration to develop RNA-targeted small molecule therapeutics. This agreement leverages Base4's pioneering drug discovery platform to identify RNA-modulating small molecules to enable and accelerate Servier's research in neuroscience drug candidates.